(D-Pro⁷)-Angiotensin I/II (1-7) |
Catalog No.GA20155
One-Click Copy Product Info
|
(D-Pro⁷)-Angiotensin I/II (1-7) is a peptide antagonist of the Mas receptor, engineered by replacing the C-terminal Pro⁷ of Angiotensin-(1-7) with a D-proline.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 586962-44-9
Sample solution is provided at 25 µL, 10mM.
(D-Pro⁷)-Angiotensin I/II (1-7) is a peptide antagonist of the Mas receptor, engineered by replacing the C-terminal Pro⁷ of Angiotensin-(1-7) with a D-proline[1]. The Mas receptor, a G-protein-coupled receptor for Ang-(1-7), elicits vasodilatory, anti-proliferative and anti-fibrotic protective signals upon activation[2]. (D-Pro⁷)-Angiotensin I/II (1-7) competitively blocks the binding of Angiotensin-(1-7) to Mas and is widely used to selectively interrupt ACE2/Ang-(1-7)/Mas-axis signaling in research[3].
In vitro, pretreatment of human pulmonary microvascular endothelial cells (PMVEC) with 100nM (D-Pro⁷)-Angiotensin I/II (1-7)(30min) completely abolished the protective effect of Ang-(1-7) against thrombin induced barrier disruption, reducing the trans-endothelial electrical resistance (TEER)[4]. In rat aortic vascular smooth muscle cells (VSMC) cultured in high glucose (25mM), 72h co-incubation with 1μM (D-Pro⁷)-Angiotensin I/II (1-7) reversed the inhibitory effect of Ang-(1-7) on high glucose-induced ErbB2 phosphorylation, restoring the p-ErbB2/t-ErbB2 ratio[5].
In vivo, (D-Pro⁷)-Angiotensin I/II (1-7) (10μM; 20min pre-incubation in isolated organ bath) reduced the maximal vasorelaxation evoked by Ang-(1-7) in rat renal arteries, completely blocking Ang-(1-7)-induced vasodilation and abolishing Ang-(1-7)-mediated activation of the NO-sGC-cGMP pathway[6]. (D-Pro⁷)-Angiotensin I/II (1-7) (0.1μM; 20min pre-incubation; vascular-bath perfusion) blocks an A-779-insensitive novel Ang-(1–7) receptor subtype and completely reverses the endothelium-dependent relaxation induced by Ang-(1–7) in isolated thoracic aortic rings from Sprague–Dawley rats[7].
References:
[1] Santos RA, Haibara AS, Campagnole-Santos MJ, et al. Characterization of a new selective antagonist for angiotensin-(1-7), D-pro7-angiotensin-(1-7). Hypertension. 2003;41(3 Pt 2):737-743.
[2] Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505-553.
[3] Santos RA, Frézard F, Ferreira AJ. Angiotensin-(1-7): blood, heart, and blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(4):383-391.
[4] Klein N, Gembardt F, Supé S, et al. Angiotensin-(1-7) protects from experimental acute lung injury. Crit Care Med. 2013;41(11):e334-e343.
[5] Akhtar S, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Benter IF. Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor. PLoS One. 2015;10(11):e0141657.
[6] Yousif MHM, Benter IF, Diz DI, Chappell MC. Angiotensin-(1-7)-dependent vasorelaxation of the renal artery exhibits unique angiotensin and bradykinin receptor selectivity. Peptides. 2017;90:10-16.
[7] Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides. 2007;28(3):702-707.
| Cell experiment [1]: | |
Cell lines | Human pulmonary microvascular endothelial cells |
Preparation Method | Human pulmonary microvascular endothelial cells (PMVECs, passages 4–8) were grown to confluence in polycarbonate wells containing gelatin-coated gold microelectrodes. Following a 30 minute recording of baseline resistance, the Ang-(1–7) receptor blocker (D-Pro⁷)-Angiotensin I/II (1-7)(100nM), the bradykinin receptor blocker icatibant (1µM), the NO synthase inhibitor Nω-nitro-L-arginine methyl ester (l-NAME; 1mM), or respective vehicle controls were added, followed after 15 minutes by Ang-(1–7) (100nM) or vehicle and after an additional 30 minutes by thrombin (0.2U/mL). Transendothelial electrical resistance (TEER) measurements were performed using an electrical cell substrate impedance sensing system. TEER values were recorded continuously up to 75 minutes after thrombin stimulation. |
Reaction Conditions | 100nM; 30min |
Applications | Pretreatment of human pulmonary microvascular endothelial cells (PMVEC) with (D-Pro⁷)-Angiotensin I/II (1-7) completely abolished the protective effect of Ang-(1-7) against thrombin induced barrier disruption, reducing the trans-endothelial electrical resistance (TEER). |
| Animal experiment [2]: | |
Animal models | Sprague–Dawley rats |
Preparation Method | 7–9-month-old male Hanover Sprague–Dawley rats were maintained in collective cages in an appropriate room with controlled temperature and with a 12h light cycle. The vasorelaxant activity of Ang-(1–7) was measured in vessels with or without functional endothelium pre-contracted to the same tension level (approximately 1.5g of tension) with submaximal concentrations of phenylephrine (0.03–0.1μM). Ang-(1–7) was added in increasing cumulative concentrations once the response to phenylephrine had stabilized. In an attempt to determine which receptor is involved in the vasorelaxant effect of Ang-(1–7), experiments were performed in endothelium-containing vessels, in the presence of the Ang-(1–7) antagonists A-779 (0.1, 1.0 or 10μM) or (D-Pro⁷)-Angiotensin I/II (1-7) (0.1μM); the B2 receptor antagonist HOE 140 (1μM), the Ang II receptor antagonists CV11974 (0.01μM; AT1 antagonist) or PD123319 (1μM; AT2 antagonist). As a control, another vessel segment from each rat was simultaneously monitored for Ang-(1–7) effects alone. |
Dosage form | 0.1μM; 20min pre-incubation, vascular-bath perfusion |
Applications | (D-Pro⁷)-Angiotensin I/II (1-7) blocks an A-779-insensitive novel Ang-(1–7) receptor subtype and completely reverses the endothelium-dependent relaxation induced by Ang-(1–7) in isolated thoracic aortic rings from Sprague–Dawley rats. |
References: | |
| Cas No. | 586962-44-9 | SDF | |
| Formula | C41H62N12O11 | M.Wt | 899.02 |
| Solubility | 1 mg/mL in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1123 mL | 5.5616 mL | 11.1232 mL |
| 5 mM | 222.5 μL | 1.1123 mL | 2.2246 mL |
| 10 mM | 111.2 μL | 556.2 μL | 1.1123 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: 98.68% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)